TITLE

Generic sales soar as patents expire

AUTHOR(S)
Chater, Amanda
PUB. DATE
August 2006
SOURCE
Drug Store News;8/28/2006, Vol. 28 Issue 10, p58
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the increase in sales of generic drugs in the United States in 2005 as patents for several branded drugs reached expiration. Apotex has launched a generic version of Plavix which is expected to affect the earnings of Plavix manufacturer, Bristol-Myers Squibb. Anchen has received approval for its generic version of Wellbutrin XL or bupropion.
ACCESSION #
22273260

 

Related Articles

  • Patent-extending tactics trouble generics makers. Chater, Amanda // Drug Store News;8/28/2006, Vol. 28 Issue 10, p56 

    The article provides an overview of the performance of the generic drug industry in the United States. It describes the impact of the expirations of branded drugs' patents on the industry. Generic drug sales increased by 20.6 percent to $22.3 billion in 2005. It is estimated that $64 billion...

  • Authorized generics debate continues.  // Drug Store News;8/28/2006, Vol. 28 Issue 10, p60 

    The article reports on the controversy over the issue of authorized generic drugs in the United States. According to the article, authorized generic drugs are those that are made by a branded drug company launched to coincide with the loss of a patent of one of their own products. To manufacture...

  • Go Go Generics.  // Pharmaceutical Executive;Dec2009, Vol. 29 Issue 12, p24 

    The article discusses developments in the market for generic drugs since the introduction of the Hatch-Waxman Act in the U.S. in 1984. It mentions that generics comprised 70 percent of prescription drugs in the country which are promoted by health plan providers and pharmacy benefit managers...

  • Best may be yet to come for generic drug makers. Kirsche, Michelle L. // Drug Store News;2/14/2005, Vol. 27 Issue 2, p28 

    Reports on the research-and-development pipeline of drug makers in the U.S. Sales of generic companies; Factors contributing to the performance of drug makers; Development of generic pipeline.

  • GPhA bullish on generic industry's future. Cohen, Harold E. // Drug Topics;5/7/2001, Vol. 145 Issue 9, p64 

    Provides information on the Generic Pharmaceutical Association (GPhA), a unification of the generic industry in the United States. Significance of the formation of a united front for the generic industry; Goals of the association; Strategy of pharmacy benefit managers.

  • Is the Generics Industry Ready for Multi-Source Biologics? Challener, Cynthia // Chemical Market Reporter;04/23/2001, Vol. 259 Issue 17, p14 

    Deals with the generic biologic industry. Estimated growth of the biopharmaceutical generics market; Details on the acquisition of Indiana Protein Technologies by Ivax Corp.; European firms preparing to participate in the marketing and sales of generic biopharmaceuticals; Risks faced by a...

  • CNS News Round-Up.  // PharmaWatch: CNS;October 2003, Vol. 2 Issue 10, p2 

    Reports on developments related to the pharmaceutical industry as of October 2003. Move of Novartis AG to license Cytos Biotechnology's Immunodrugs against Alzheimer's disease; Approval from the U.S. Food and Drug Administration granted to GlaxoSmithKline PLC to expand the indications of Paxil...

  • SEE pharmaceutical market healthy in 2010. Stamov, Valentin; Pavlova, Iskra // SEE Top 100;2011, p46 

    The article focuses on the condition of the pharmaceutical market in 2010 in Southeast Europe (SEE). It notes that sales of pharmaceuticals in the SEE region are influenced by generic drugs. It claims that there is a growth in the pharmaceutical market in Bulgaria in terms of value. It also...

  • Antihypertensives: Generics striking at heart of the market.  // PharmaWatch: Monthly Review;Jan2007, Vol. 6 Issue 1, p13 

    The article focuses on the declining growth rate of the antihypertensive drug market in the U.S. which has been attributed to the penetration of generic drugs. It is cited that the slow growth rate does not manifest a stationary market, but a battle between generic drugs and branded ones....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics